Clinical Trials Directory

Trials / Completed

CompletedNCT03389607

The Role of SCUBE-1 in Ischemia-reperfusion Injury

The Role of SCUBE-1 in Ischemia-reperfusion Injury in Patients With Knee Prosthesis

Status
Completed
Phase
Study type
Observational
Enrollment
15 (actual)
Sponsor
Diskapi Yildirim Beyazit Education and Research Hospital · Other Government
Sex
All
Age
18 Years – 70 Years
Healthy volunteers
Not accepted

Summary

One consequence of tissue damage caused by tourniquet is ischemia-reperfusion injury. Short-term ischemia leads to vasodilatation and reactive hyperemia resulting in post-ischemic reperfusion microcirculation failure and tissue edema that extends from 30 minutes to 4 hours. SCUBE-1 is a newly defined cell surface molecule. It emerges from many developing cells, including endothelium and platelets. Immunohistochemical demonstration of subendothelial matrix deposition in atherosclerosis in humans. We did not find any study that showed the post-ischemic regression of scube 1, which was shown to be significantly higher in ischemic events in the literature. in this study is aimed to investigate the location / sensitivity of SCUBE-1 in diabetics and nondiabetics after application of regional anesthesia for ischemia-reperfusion injury induced by tourniquet application in knee prosthesis attempts in our aimed patients and compare this with other total antioxidant status (TAS) and MDA of ischemia-reperfusion parameters

Detailed description

After being taken to the operation room, the patient will be divided into two groups as group D (diabetic) and group K (control) by standardized anesthesia monitoring with 5-lead electrocardiogram (ECG), peripheral oxygen saturation (SpO2) and noninvasive blood pressure measurements. In both groups, spinal anesthesia will be applied in a lateral decubitus position using a 22 gauge Quincke spinal needle from the interspinal space as 0.5% heavy marcaine 10-12.5 mg 1 min. Atropine 0.5 mg and ephedrine 5 mg should be administered if bradycardia develops in both groups. The disease tourniquet will be applied after induction, in accordance with the literature, to be above 150 mmHg of the systolic blood pressure.

Conditions

Interventions

TypeNameDescription
DIAGNOSTIC_TESTspinal anesthesiabefore spinal anesthesia, before 5 min opening of tourniquet and 2 hr after operation SCUBE-1, MDA and TAC will measured from plasma

Timeline

Start date
2018-01-08
Primary completion
2018-09-01
Completion
2019-02-01
First posted
2018-01-03
Last updated
2019-10-09

Locations

1 site across 1 country: Turkey (Türkiye)

Source: ClinicalTrials.gov record NCT03389607. Inclusion in this directory is not an endorsement.